Sjc 13

Sjc 13 (1 mg/mL; 1 h pre-incubation, 4 h/24 h Lipopolysaccharides, from E. coli O111:B4 (LPS) (HY-D1056A1) stimulation) completely inhibits the adhesion of HL60 cells to LPS-stimulated HUVECs at 4 h after stimulation, but exerts no effect on adhesion at 24 h after stimulation^[2].
Sjc 13 (1 mg/mL; 1 h pre-incubation, 4 h/24 h LPS stimulation) inhibits LPS-induced expression of E-selectin (expression reduced by 95%) and VCAM-1 (expression reduced by 94%) on human umbilical vein endothelial cells (HUVEC), but does not affect ICAM-1 expression and has no impact on basal adhesion molecule levels^[2].
Sjc 13 (62.5-1000 μg/mL; 1 h pre-incubation, 4 h/24 h LPS stimulation) exerts a stronger inhibitory effect on LPS-induced expression of E-selectin (IC₅₀ = 150 μg/mL) and VCAM-1 (IC₅₀ = 115 μg/mL) in human umbilical vein endothelial cells (HUVEC) than on LPS-induced ICAM-1 expression (IC₅₀ = 760 μg/mL), and exhibits concentration-dependent activity in the range of 62.5 to 1000 μg/mL^[2].
Sjc 13 (1 mg/mL; 1 h pre-incubation, 4 h LPS stimulation) inhibits LPS-induced mRNA expression of E-selectin and VCAM-1 in human umbilical vein endothelial cells (HUVEC), but does not affect LPS-induced ICAM-1 mRNA levels^[2].
Sjc 13 inhibits the adhesion of HL60 cells to LPS-stimulated HUVECs, and selectively suppresses the expression and mRNA synthesis of E-selectin and VCAM-1 in LPS-stimulated HUVECs when administered 1-2 h after LPS stimulation; its activity is lost if it is added 2 h after LPS stimulation^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.